Table 3.
Risk factors for BOS and RAS by 3 years post-LT as compared to stable recipients (univariate multinomial analysis).
| Variable | BOS |
RAS |
|||
|---|---|---|---|---|---|
| OR (95% CI) | p-value | OR (95% CI) | p-Value | ||
| Recipient age | 1.000 (0.980, 1.021) | 0.974 | 1.031 (1.003, 1.060) | 0.030 | |
| Donor age | 1.005 (0.985, 1.025) | 0.623 | 1.015 (0.990, 1.040) | 0.235 | |
| Difference of R/D age | 0.996 (0.979, 1.014) | 0.683 | 1.008 (0.987, 1.030) | 0.433 | |
| Recipient smoking history | Yes | 1.420 (0.750, 2.687) | 0.282 | 2.358 (1.048, 5.303) | 0.038 |
| Recipient BMI | 1.014 (0.944, 1.089) | 0.704 | 1.107 (1.024, 1.197) | 0.011 | |
| Underlying diagnosis | CF | Baseline | Baseline | ||
| COPD | 1.690 (0.736, 3.882) | 0.216 | 3.018 (1.016, 8.966) | 0.047 | |
| ILD/IPF | 2.233 (0.870, 5.736) | 0.095 | 7.258 (2.444, 21.559) | <0.001 | |
| Other | 2.144 (0.833, 5.207) | 0.092 | 0.447 (0.051, 3.897) | 0.466 | |
| Sum of HLA mismatches | 0.973 (0.706, 1.342) | 0.870 | 1.180 (0.771, 1.805) | 0.446 | |
| Max cold ischemia time | 1.000 (0.996, 1.003) | 0.904 | 0.998 (0.994, 1.003) | 0.472 | |
| Induction treatment | Basiliximab | Baseline | Baseline | ||
| None | 2.000 (0.870, 4.598) | 0.103 | 1.571 (0.654, 3.774) | 0.312 | |
| rATG | 4.532 (2.060, 9.972) | <0.001 | 0.985 (0.326, 2.977) | 0.979 | |
| PGD stage 3 | Yes | 0.576 (0.066, 5.050) | 0.618 | 0.993 (0.112, 8.819) | 0.995 |
| Immunosuppression | Cyclosporin | Baseline | Baseline | ||
| Tacrolimus | 0.957 (0.495, 1.850) | 0.897 | 0.379 (0.170, 0.846) | 0.018 | |
| Y1 t-AR | 1.110 (0.802, 1.536) | 0.530 | 0.826 (0.505, 1.352) | 0.448 | |
| Y1 t-infections | 0.962 (0.803, 1.153) | 0.678 | 1.087 (0.904, 1.308) | 0.375 | |
| Y1 t-CMV | 1.303 (0.721, 2.355) | 0.380 | 0.763 (0.304, 1.915) | 0.565 | |
| DSA before LT | Yes | 2.850 (1.305, 6.223) | 0.009 | 1.900 (0.714, 5.055) | 0.199 |
| Y1 DSAs (I or II) | Yes | 3.048 (1.450, 6.406) | 0.003 | 3.048 (1.254, 7.409) | 0.014 |
| Y1 DSAs I | Yes | 3.060 (1.214, 7.714) | 0.018 | 1.394 (0.364, 5.332) | 0.628 |
| Y1 DSAs II | Yes | 3.550 (1.631, 7.726) | 0.001 | 3.328 (1.313, 8.434) | 0.011 |
Statistically significant results are highlighted in bold.
Results are presented as OR (95% confidence intervals). For binary variables, the “No” group has been considered the baseline group.
AR, acute cellular rejection episodes; BMI, body mass index; CF, cystic fibrosis; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease; D, donor; DSAs, donor-specific antibodies; HLA, human leukocyte antigen; ILD/IPF, interstitial lung disease/idiopathic pulmonary fibrosis; LT, lung transplantation; R, recipient; t, treated; PGD, primary graft dysfunction; rATG, rabbit antithymocyte globulin; Y1, year 1; BOS, bronchiolitis obliterans syndrome; RAS, restrictive allograft syndrome; OR, odds ratio.